Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718628 | 1.00 | HTR2A (0.42) | HTR2ATAAR1CYP2C19HRH1LMNA | |
| SCHEMBL2095864 | 0.77 | HRH1 (0.46) | HTR2ATAAR1CYP2C19HRH1LMNA | |
| SCHEMBL2095865 | 0.77 | HRH1 (0.46) | HTR2ATAAR1CYP2C19HRH1LMNA | |
| SCHEMBL691762 | 0.75 | CYP2C19 (0.57) | HTR2ATAAR1CYP2C19HRH1TDP1 | |
| SCHEMBL8599444 | 0.74 | LMNA (0.46) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL8599440 | 0.74 | LMNA (0.46) | HTR2ATAAR1HRH1LMNATDP1 | |
| SCHEMBL7245503 | 0.74 | HTR2A (0.41) | HTR2ATAAR1CYP2C19HRH1LMNA | |
| SCHEMBL7244288 | 0.74 | HTR2A (0.41) | HTR2ATAAR1CYP2C19HRH1LMNA | |
| SCHEMBL28692144 | 0.74 | HTR2A (0.59) | HTR2ATAAR1CYP2C19HRH1LMNA | |
| SCHEMBL5405861 | 0.74 | LMNA (0.41) | HTR2ATAAR1CYP2C19HRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1335912-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002042291-A1 | 4-(BIPHENYLCARBONYLAMINO)PIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034028-A1 | 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors | LIPC, CETP, MTTP | HTR2A 2250/4885TAAR1 569/4885CYP2C19 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.